<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03489772</url>
  </required_header>
  <id_info>
    <org_study_id>ITI-214-106</org_study_id>
    <nct_id>NCT03489772</nct_id>
  </id_info>
  <brief_title>Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind Study of Escalating Single Doses of ITI-214 in Healthy Volunteers to Determine Central Nervous System Engagement, Safety and Tolerability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intra-Cellular Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laureate Institute for Brain Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Intra-Cellular Therapies, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single site, randomized, double-blind, placebo-controlled, within-subjects study
      design in healthy volunteers. Escalating single doses of ITI-214 will be evaluated using
      functional magnetic resonance imaging (fMRI) to determine central nervous system engagement.
      Safety and tolerability also will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BOLD MRI signals in the anterior insula during the extinction phase of a Fear Conditioning task</measure>
    <time_frame>1-3 hours post-dose</time_frame>
    <description>Changes in brain activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BOLD MRI signals in the inferior frontal gyrus during the Stop Signal Task</measure>
    <time_frame>1-3 hours post-dose</time_frame>
    <description>Changes in brain activation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BOLD fMRI signals elicited by fear conditioning stimulus</measure>
    <time_frame>1-3 hours post-dose</time_frame>
    <description>Changes in brain activation in amygdala, prefrontal cortex, and/or insula cortex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOLD fMRI signals elicited by the Stop versus Go signal</measure>
    <time_frame>1-3 hours post-dose</time_frame>
    <description>Changes in brain activation in dorsolateral prefrontal cortex and/or anterior cingulate cortex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with reported or observed treatment-related adverse events</measure>
    <time_frame>0-5 hours post-dose</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <other_outcome>
    <measure>BOLD fMRI signals elicited in the amygdala, insula and medial prefrontal cortex</measure>
    <time_frame>1-3 hours post-dose</time_frame>
    <description>Pharmacodynamics</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1 mg ITI-214</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg ITI-214</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ITI-214</intervention_name>
    <description>Oral</description>
    <arm_group_label>1 mg ITI-214</arm_group_label>
    <arm_group_label>10 mg ITI-214</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female, 18 - 45 years

          -  Fluent and literate in English and able to provide written informed consent

          -  BMI between 18.5 and 38.0 kg/m2 and minimum body weight of 50 kg

        Exclusion Criteria:

          -  Recent exposure to any investigational product

          -  Previous exposure to relevant fMRI task(s)

          -  Considered medically unsuitable for participation

          -  Has any contraindication for BOLD fMRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Davis, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Intra-Cellular Therapies, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Davis, PhD</last_name>
    <phone>646-440-9333</phone>
    <email>itciclinicaltrials@intracellulartherapies.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Laureate Institute for Brain Research, Inc.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sahib S Khalsa, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

